Jeremy Grantham Protagonist Therapeutics, Inc Transaction History

Grantham, Mayo, Van Otterloo & Co. LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 13, 2020	SELL	$6.19 - $18.84 $113,277 - $344,772	-18,300 Closed	0 $0
Q1 2020 May 14, 2020	SELL	$5.4 - $9.22 $9,180 - $15,674	-1,700 Reduced 8.5%	18,300 $129,000
Q4 2019 Feb 13, 2020	SELL	$4.69 - $13.45 $86,296 - $247,480	-18,400 Reduced 47.92%	20,000 $141,000
Q3 2019 Nov 13, 2019	BUY	$9.41 - $16.56 $361,344 - $635,904	38,400 New	38,400 $461,000

247

56.4M

76.3K

114K

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $2.2B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

Get notified when there are updates to the investment portfolio of Grantham, Mayo, Van Otterloo & Co. LLC, based on Form 13F filings with the SEC.

Stay updated on Grantham, Mayo, Van Otterloo & Co. LLC and Jeremy Grantham with notifications on news.